75 related articles for article (PubMed ID: 15140582)
41. Application of HPLC-ESI-ITMS in the quality control of carboxyterminal sequence confirmation for the recombinant DNA product Hirudin Variant 3.
Huang XD; Tong WW; Fan XL; Li ZH
J Pharm Biomed Anal; 2007 Jan; 43(2):533-9. PubMed ID: 17141443
[TBL] [Abstract][Full Text] [Related]
42. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
43. Characterization of the urinary metabolites of dipetarudin.
López M; Nowak G
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):210-4. PubMed ID: 15927544
[TBL] [Abstract][Full Text] [Related]
44. [Heparin-induced thrombocytopenia type II. Intra- and postoperative lepirudin treatment in acute ischemia of the extremities].
Schmidt O; Lang W
Dtsch Med Wochenschr; 1998 Oct; 123(41):1207-10. PubMed ID: 9810286
[TBL] [Abstract][Full Text] [Related]
45. Lepirudin prevents lethal effects of Shiga toxin in a canine model.
Raife T; Friedman KD; Fenwick B
Thromb Haemost; 2004 Aug; 92(2):387-93. PubMed ID: 15269836
[TBL] [Abstract][Full Text] [Related]
46. [Biventricular thrombi dissolution and antibody development with lepirudin therapy].
Skowasch D; Pötzsch B; Kuntz-Hehner S; Gampert T; Rox J; Omran H; Bauriedel G; Lüderitz B
Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1531-4. PubMed ID: 12854062
[TBL] [Abstract][Full Text] [Related]
47. Lepirudin anaphylaxis and Kounis syndrome.
Koutsojannis CM; Kounis NG
Circulation; 2004 Jun; 109(22):e315; author reply e315. PubMed ID: 15184302
[No Abstract] [Full Text] [Related]
48. Enhanced secretion of adhesive recognition sequence containing hirudin III mutein in E. coli.
Tan S; Wu W; Li X; Cui L; Li B; Ruan Q
Mol Biotechnol; 2007 May; 36(1):1-8. PubMed ID: 17827531
[TBL] [Abstract][Full Text] [Related]
49. Protein-Engineered Hirudins with Enhanced Anticoagulant Activities Developed by a Molecular Integrative Approach.
Sun Y; Wang D
J Med Chem; 2024 Mar; 67(5):3203-3204. PubMed ID: 38382050
[No Abstract] [Full Text] [Related]
50. Hirudin in heparin-induced thrombocytopenia.
Lubenow N; Greinacher A
Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
[TBL] [Abstract][Full Text] [Related]
51. Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis.
Willey ML; de Denus S; Spinler SA
Pharmacotherapy; 2002 Apr; 22(4):492-9. PubMed ID: 11939684
[TBL] [Abstract][Full Text] [Related]
52. Characterization of the postglomerular renal metabolism of lepirudin in healthy volunteers.
Kautzleben M; Stein G; Sperschneider H; Nowak G
Thromb Res; 2004; 113(3-4):187-95. PubMed ID: 15140582
[TBL] [Abstract][Full Text] [Related]
53. Characterization of C-terminal-truncated urinary metabolites of a recombinant hirudin in rats.
Komatsu Y; Hayashi H
Peptides; 1999 Dec; 20(12):1401-9. PubMed ID: 10698114
[TBL] [Abstract][Full Text] [Related]
54. Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant.
Salmela B; Joutsi-Korhonen L; Saarela E; Lassila R
Thromb Res; 2010 Jun; 125(6):538-44. PubMed ID: 20181379
[TBL] [Abstract][Full Text] [Related]
55. Sites of elimination and pharmacokinetics of recombinant [131I]lepirudin in baboons.
Meiring SM; Lötter MG; Badenhorst PN; Bucha E; Nowak G; Kotzé HF
J Pharm Sci; 1999 May; 88(5):523-9. PubMed ID: 10229643
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
